Establishment Labs Holdings stock
ESTANASDAQEstablishment Labs Holdings Inc., HealthcareISIN VGG312491084
41Score 41 out of 100, Weak
Price and trend
62 / 100
Price history
+8.6% in one yearThe chart shows daily closes over 8 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 5.2% below it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 57).
The price is 28% below its 52-week high. Largest decline in 8 years: 75% (July 2021 to November 2023).
Chart figures for advanced users
- SMA 50$66.07
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$72.38
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)57
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$54.69
- The lowest closing price of the last twelve months.
- Resistance$95.65
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Establishment Labs Holdings Inc. belongs to the Medical (Devices) industry (United States) and, with a market value of $2.05B, is number 40 of 88 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $211.08M (up 27.1% year on year) and a loss of $51.06M.
- For fiscal 2026, analysts expect on average revenue of $274.8M (up 30.2%) and adjusted earnings per share of −$1.38.
Show more
- MEQIRI Score 41 out of 100 (Weak): rank 527 of 702 in Healthcare, median 53.
- Our model puts fair value at $65.63, with the price 5% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- High debtDebt 17.28 times equity (latest quarter), Medical (Devices) median 0.47.Stability 30
- DilutionShare count up 27% since 2020.Capital allocation 18
- Loss-makingLoss of $38.45M over the last 12 months.Fundamentals 17
Its standout strength is growth, while capital allocation and fundamentals hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high price swings
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $46.88 and expensive above $109.39 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $52.62, at 7.8% it would be $85.33.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 38.3% on the twelve months before. Revenue has grown strongly since 2016, at around 30% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 69%, operating −18%, net −24%. Last 12 months: net −15%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 23 Feb 2027in 102 days
- Last reported
- 29 Oct 2026EPS reported −$0.35 (expected −$0.26)below expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 625.3% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$1.38−14.5%
- Revenue
- $274.8M+1.7%
- Earnings per share
- −$0.11−625.3%
- Revenue
- $342.91M+1.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −9.4%Establishment Labs raised its 2026 revenue guidance to more than $274 million, up from $269 to $271 million, and expects 25% growth in 2027.
“Our fourth quarter is off to a strong start, giving us confidence to raise our full year 2026 revenue guidance to more than $274 million, up from a previous range of $269 million to $271 million. Our 2026 success should carry over into 2027, and we expect 25% revenue growth next year.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 29 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $8.1M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Establishment Labs Holdings
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 41
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- NeogenNEOG $2.44B41
- UFP TechnologiesUFPT $2.37B76
- Drägerwerk AG & Co. KGaADRW3.DE $2.31B66
- ElektaEKTA-B.ST $2.27B56
- Butterfly NetworkBFLY $1.78B45
- Embla Medical hf.EMBLA.CO $1.76B67
- ChemoMetecCHEMM.CO $1.76B78
- Inspire Medical SystemsINSP $1.75B52
ETFs that hold Establishment Labs Holdings
Held by 11 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Ageing Population UCITS ETF2B77 | 0.15% | 0.40% | €813.42M |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.06% | 0.30% | €4.28B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.06% | 0.30% | €2.22B |
Show 5 more
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.06% | 0.30% | €185.82M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.04% | 0.43% | €2.5B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.04% | 0.10% | €395.74M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.01% | 0.35% | €8.27B |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.00% | 0.25% | €178.55M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jul 2019)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.